NLS Pharmaceutics AG R&D Update Transcript
Good morning and good afternoon, everyone. I would like to welcome you all to today's presentation at the NLS Pharmaceutics pipeline and development strategies. We will have an opportunity for Q&A at the end, and you can submit your questions electronically to me, and I will read those to the panel.
Before we start, just a quick reminder of the Safe Harbour. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 6-K that was filed with and furnished to the US Securities and Exchange Commission in conjunction with this webcast. A recording of the webcast, including the Q&A session, will be available on our website within the coming days.
With that, I would like to introduce you all to our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |